Transformative vascular implants
Addressing major life-threatening diseases, backed by Nobel-winning science
aXess™
Living Access
Starts Now
aXess™ is a medical device for patients requiring vascular access for hemodialysis. At implantation the patient’s own cells infiltrate the porous scaffold and begin early tissue integration. Post implantation aXess™ is ready for cannulation after 14 days. Over time, it transforms into each patient’s own living vessel for reliable vascular access.
TECHNOLOGY
ABOUT
Xeltis is an an international medtech company with business with roots in the Netherlands and commercial and clinical operations throughout Europe and the US. We are a passionate and driven team, with expertise from world-renowned universities and innovative life science companies, backed by high-quality advisors and investors.
About
TECHNOLOGY
Xeltis is developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue.
The natural creation of living and long-lasting vessels reduce risk of:
-
Thrombosis
-
Infection
-
Reinterventions
-
Long-term calcification and stenosis
Our groundbreaking implants are transforming the treatment of life-threatening diseases. Built on Restorex®, our proprietary technology, leveraging Nobel Prize-winning breakthroughs in supramolecular chemistry and polymer technology which enables transformation to the patient’s tissue.
Technology
Xeltis outlines plans for aXess™, its revolutionary vascular access conduit for dialysis.
With Eliane Schutte, CEO of Xeltis.
Play Video
Watch Video
APPLICATIONS
Xeltis aims to improve the standard of care for millions of patients who undergo vascular surgery every year, including hemodialysis access, peripheral arterial and coronary arterial bypass surgeries.
Future expansions for our Restorex® supramolecular polymer technology include pulmonary heart valves and other vascular indications, such as peripheral arterial disease.
Xeltis aims to meet the needs of patients and healthcare providers by providing bioresorbable, non-immunogenic implants that transform into the patient’s own tissue, with a low risk of infection and reduced need for reintervention.
Applications
How to “build” a new blood vessel- the natural way
With Eliane Schutte, CEO of Xeltis.
Play Video
Watch Video
PATIENTS
Xeltis is transforming vascular access by developing transformative implants designed to reduce repeat surgeries, complications and reinterventions, helping patients around the world achieve better long-term outcomes.
Visit our Patients page for an overview of our ongoing clinical trials.
Patients
LATEST NEWS
Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis